With the help of a partnership with WuXi AppTec’s LabNetwork, SAMDI’s small molecule screening collection now has well over a million compounds available to screen against targets
SAMDI Tech has announced it has passed the one million compounds mark in its small molecule screening collection. The milestone was hit, in part, through a partnership with WuXi AppTec’s LabNetwork, a global e-commerce platform connecting chemistry and research communities worldwide.
The partnership will provide Samdi access to WuXi’s commercial collection of more than 300,000 compounds, further diversifying the number of compounds and compound class choices available on its platform.
Emilio Córdova, CEO of Samdi said: “We are committed to helping our clients advance their drug discovery pipelines. By increasing the chance of finding a hit with the right characteristics for development, we ultimately help clients bring new and better therapies to market for patients around the world.”
Samdi technology assesses a drug candidate’s potential. Its high-throughput assay services include setup, preparation, and execution for a number of screening phases.
Xuanjia Peng, the head of WuXi-LabNetwork, said: “WuXi-LabNetwork is pleased to make the WuXi compounds available to Samdi Tech’s customers through this new arrangement. Now customers who choose their label-free technology can also access the novel compounds from WuXi.”
Samdi Tech, the label-free drug discovery solutions, simplifies and streamlines drug candidate screening using its high-throughput SAMDI (Self-Assembled Monolayer Desorption Ionization) assay.